HAI Book 2026 - Flipbook - Page 381
Lopresti, Brian J
Standardized expression of longitudinal tau accumulation using the
CenTauR scale
Alexis Moscoso Rial1,2, Antoine Leuzy1,3, Lars Lau Raket4, Gregory Klein5, Hartmuth C Kolb3,
Leonardo Iaccarino4, Christopher C Rowe6,7,8, Ziad S Saad9, Clifford R Jack Jr10, Christopher G
Schwarz10, Matteo Tonietto5, Yashmin Karten1, Nadine Tatton1, Alex DelBene11, Alexandra
Gogola11, Victor L Villemagne12, Vincent Doré7,13, Brian J Lopresti11
Critical Path for Alzheimer’s Disease (CPAD) Consortium, Critical Path Institute, Tucson, AR, US
Nuclear Medicine Department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de
Compostela, Santiago de Compostela, ES
3
Enigma Biomedical Group, Knoxville, TN, US
4
Eli Lilly and Company, Indianapolis, IN, US
5
F. Hoffmann-La Roche Ltd, Basel, CH
6
Department of Molecular Imaging & Therapy, Austin Health, Victoria, AU
7
Florey Department of Neuroscience, University of Melbourne, Victoria, AU
8
The Australian Dementia Network (ADNeT), The University of Melbourne, Victoria, AU
9
Johnson & Johnson, San Diego, CA, US
10
Department of Radiology, Mayo Clinic, Rochester, MN, US
11
Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, US
12
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, US
13
Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Victoria, AU
1
2
Introduction: The CenTauR framework has proven effective for harmonizing tau-PET quantitative metrics across
radiotracers and quantification pipelines. However, its longitudinal consistency has not yet been evaluated. This
study assessed rates of tau accumulation expressed in the CenTauR scale across clinical trials and observational
studies to determine the consistency of longitudinal tau-PET changes across populations scanned with different
radiotracers.
Methods: Participants were included from the placebo and treatment arms of three clinical trials4A4 (n = 344;
[¹⁸F]flortaucipir), TANGO (n = 296; [¹⁸F]MK-6240), and Tilavonemab (n = 106; [¹⁸F]MK-6240)4as well as from the
observational ADNI study (n = 219; [¹⁸F]flortaucipir). All clinical trials showed nonsignificant treatment effects on
tau-PET. Participants were amyloid-β3positive and had a baseline and at least one follow-up tau-PET scan.
CenTauR values within the Meta-Temporal region of interest were computed using a standardized SPM12-based
SUVR quantification pipeline and Joint Propagation Model3derived conversion equations (Moscoso et al.,
Alzheimer’s Imaging Consortium, 2025). Longitudinal change in CenTauR values was estimated using linear mixedeffects models including baseline CenTauR and trial/cohort as covariates. Models were fitted separately for
cognitively unimpaired (CU) and cognitively impaired (CI) groups.
Results: Among CI participants, the mean annual change in CenTauRs was consistent across the clinical trials
using [¹⁸F]MK-6240 (TANGO: 3.9 CenTauRs, 95% CI [3.034.9]; Tilavonemab: 4.4 CenTauRs, 95% CI [1.337.4]) and
the ADNI study, which used [¹⁸F]flortaucipir (3.7 CenTauRs, 95% CI [1.735.6]) (Figure 1A). Similarly consistent
results were observed among CU participants scanned with [¹⁸F]flortaucipir in A4 (mean 4-year change: 6.1
CenTauRs, 95% CI [5.536.8]) and ADNI (8.4 CenTauRs, 95% CI [5.6311.2]) (Figure 1B).
HAI2026 – Page 381
